Study analysis · European Heart Journal · 2024
After a heart attack, hitting cholesterol targets was linked to up to 37% lower relative risk of another major heart event — but we still don't know how many people that actually helps.
In people who survived a heart attack or unstable angina, getting cholesterol and triglyceride levels down to recommended targets one year later was linked to fewer future heart attacks, strokes, and heart-related deaths, but the study cannot prove cause and effect.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study watched people who had a heart attack or related problem and compared those with lower cholesterol to those with higher cholesterol over time. It can show a link between lower cholesterol and fewer future heart problems, but it cannot prove that the lower cholesterol itself caused the improvement. Only a randomized experiment could prove cause and effect.
What’s the bottom line?
A study followed 2,579 people who had a heart attack or unstable angina. One year later, those who reached lower cholesterol targets had fewer future heart problems compared with those who did not.
How strong is this study?
The study followed a large group of people for several years and tried to account for some differences like age and smoking, which is a strength. However, because people were not randomly assigned to different cholesterol levels, other hidden differences could explain the results. Also, we only have the summary, not the full details, so we cannot fully check how well it was done.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
38 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=2579)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with no randomization. Participants were not randomly assigned to different lipid levels or treatments, so residual confounding, selection bias, and reverse causation cannot be ruled out. Therefore, it can show associations but cannot prove that achieving lower lipid levels or targets causes the reduction in MACE.
COI Unknown
Could not determine conflict of interest status
The provided text is only an abstract and contains no conflict of interest or funding disclosure, so no COI assessment can be made.
Abstract only; no author affiliations, COI, or funding sections included. The cohort name SPUM-ACS may have external funding, but this is not stated in the provided text.
Key takeaways
- 01
Reaching LDL cholesterol below 1.8 mmol/L was linked to a 29% lower relative risk of future heart attack, stroke, revascularization, or heart death (HR 0.71).
- 02
A 50% or greater drop in LDL was linked to a 37% lower relative risk (HR 0.63).
- 03
Non-HDL below 2.2 mmol/L was linked to a 35% lower relative risk (HR 0.65).
- 04
Triglycerides below 1.7 mmol/L was linked to a 24% lower relative risk (HR 0.76).
- 05
These are relative risk reductions.
- 06
The study did not report how many people actually had events, so we cannot say how many fewer cases per 1,000 people this means.
- 07
Without absolute event numbers, the real-world size of the benefit for an individual is unclear.
Practical takeaways
If you have had ACS, discuss with your clinician whether you are meeting guideline lipid targets: LDL-C below 1.8 mmol/L or a 50% or greater reduction from baseline, non-HDL-C below 2.2 mmol/L, and triglycerides below 1.7 mmol/L.
This is an observational cohort; it cannot prove that hitting targets causes lower risk. Absolute risk reduction was not reported, and this analysis is based on the abstract only, not the full paper.
low confidenceTrack both your absolute lipid level and the percentage change from baseline after ACS, since the study linked a 50% or greater LDL drop with the largest relative risk reduction.
The study did not report how many actual events were prevented. Full methodology and absolute event rates were not available in the abstract.
low confidenceWhy this study matters
The biggest relative risk drop: cutting LDL by at least half
In 2,579 ACS survivors, achieving a 50% or greater reduction in LDL cholesterol from baseline one year after ACS was associated with HR 0.63 (95% CI 0.48–0.84), or a 37% lower relative risk of subsequent MACE over a median 5.5 years. Achieving LDL-C below 1.8 mmol/L was associated with HR 0.71 (95% CI 0.54–0.93), or a 29% lower relative risk. Absolute risk reduction was not reported.
Many people focus on hitting a single LDL number, but the percentage drop from baseline was linked to an even larger relative risk reduction in this cohort.
Triglycerides also tracked with lower relative risk
Achieving triglycerides below 1.7 mmol/L one year after ACS was associated with HR 0.76 (95% CI 0.62–0.94), a 24% lower relative risk of MACE. Each 1 mmol/L reduction in triglycerides was associated with a 14% lower relative risk.
Triglycerides are often overlooked compared with LDL, but this real-world cohort found a link between hitting the triglyceride target and fewer future events.
Real-world data, but not proof of cause and effect
This was an observational Swiss multicentric cohort (SPUM-ACS, 2007–2021). Cox models adjusted for age, sex, BMI, smoking, statin intensity, diabetes, systemic inflammatory disease, and creatinine. Even so, the design cannot prove that lipid targets cause the lower risk; residual confounding is possible.
It reflects what happens in actual clinical practice, not a tightly controlled trial. But it cannot settle causation.
Most patients were already on statins
At discharge, 98% were prescribed statin therapy (59% high-intensity); one year after ACS, 92% were on statins (50% high-intensity). Median LDL-C fell from 3.7 to 2.4 mmol/L (a 34% drop) during the first year.
Even in a heavily statin-treated population, achieving lower lipid targets was linked to lower relative risk — suggesting residual risk may remain when targets are not met.
Subgroups showed consistent signals
The abstract reports that neither age, sex, BMI, diabetes, nor smoking status affected the results (p for interaction ≥0.05). This means the association between lipid target achievement and lower MACE risk appeared similar across these subgroups.
It suggests the link is not limited to one demographic group, though subgroup analyses in observational studies still need cautious interpretation.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A study followed 2,579 people who had a heart attack or unstable angina. One year later, those who reached lower cholesterol targets had fewer future heart problems compared with those who did not.
Research results
Reaching LDL cholesterol below 1.8 mmol/L was linked to a 29% lower relative risk of future heart attack, stroke, revascularization, or heart death (HR 0.71). A 50% or greater drop in LDL was linked to a 37% lower relative risk (HR 0.63). Non-HDL below 2.2 mmol/L was linked to a 35% lower relative risk (HR 0.65). Triglycerides below 1.7 mmol/L was linked to a 24% lower relative risk (HR 0.76).
What this means - more context
These are relative risk reductions. The study did not report how many people actually had events, so we cannot say how many fewer cases per 1,000 people this means. Without absolute event numbers, the real-world size of the benefit for an individual is unclear.
To evaluate whether achieved and reduced lipid levels one year after acute coronary syndrome (ACS) are associated with subsequent major adverse cardiovascular events (MACE) in a real-world setting.
In 2,579 ACS survivors, achieving lipid targets one year after ACS was associated with lower relative risk of subsequent MACE over a median 5.5 years: LDL-C <1.8 mmol/L 29% lower relative risk (HR 0.71), LDL-C reduction ≥50% 37% lower relative risk (HR 0.63), non-HDL-C <2.2 mmol/L 35% lower relative risk (HR 0.65), and triglycerides <1.7 mmol/L 24% lower relative risk (HR 0.76). Absolute risk reduction was not reported. This is an observational cohort, so associations do not prove causation.
Methods Used
SPUM-ACS, a Swiss multicentric cohort of patients hospitalized with ACS between 2007 and 2021. 2,579 ACS survivors attended a one-year follow-up visit with lipid measurements and were followed for MACE (myocardial infarction, stroke, coronary revascularization, cardiovascular death) over a median of 5.5 years. Cox proportional hazards models were adjusted for age, sex, BMI, smoking status, statin therapy intensity, diabetes, systemic inflammatory disease, and creatinine.
Main Finding
One year after ACS, achieving LDL-C <1.8 mmol/L was associated with a 29% lower relative risk of MACE (HR 0.71, 95% CI 0.54-0.93); LDL-C reduction ≥50% with a 37% lower relative risk (HR 0.63, 95% CI 0.48-0.84); non-HDL-C <2.2 mmol/L with a 35% lower relative risk (HR 0.65, 95% CI 0.51-0.83); and triglycerides <1.7 mmol/L with a 24% lower relative risk (HR 0.76, 95% CI 0.62-0.94). Each 1 mmol/L reduction in LDL-C, non-HDL-C, and triglycerides was associated with 23%, 24%, and 14% lower relative risk, respectively. Absolute risk reduction was not reported in this study.
Confidence Level
Limited to moderate: large observational cohort with adjusted Cox models, but abstract-only review; no absolute risk reported; residual confounding possible; causal inference cannot be made.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Observational design cannot prove causation
- •Absolute risk reduction not reported in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
If you have had ACS, discuss with your clinician whether you are meeting guideline lipid targets: LDL-C below 1.8 mmol/L or a 50% or greater reduction from baseline, non-HDL-C below 2.2 mmol/L, and triglycerides below 1.7 mmol/L.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study watched people who had a heart attack or related problem and compared those with lower cholesterol to those with higher cholesterol over time. It can show a link between lower cholesterol and fewer future heart problems, but it cannot prove that the lower cholesterol itself caused the improvement. Only a randomized experiment could prove cause and effect.
Strengths
- Large sample size (2,579 ACS survivors)
- Multicentric Swiss cohort (SPUM-ACS)
- Long median follow-up of 5.5 years after the one-year post-ACS visit
Weaknesses
- Full methodology not available - based on abstract only
- Observational cohort design with no randomization
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A study followed 2,579 people who had a heart attack or unstable angina. One year later, those who reached lower cholesterol targets had fewer future heart problems compared with those who did not.
Research results
Reaching LDL cholesterol below 1.8 mmol/L was linked to a 29% lower relative risk of future heart attack, stroke, revascularization, or heart death (HR 0.71). A 50% or greater drop in LDL was linked to a 37% lower relative risk (HR 0.63). Non-HDL below 2.2 mmol/L was linked to a 35% lower relative risk (HR 0.65). Triglycerides below 1.7 mmol/L was linked to a 24% lower relative risk (HR 0.76).
What this means - more context
These are relative risk reductions. The study did not report how many people actually had events, so we cannot say how many fewer cases per 1,000 people this means. Without absolute event numbers, the real-world size of the benefit for an individual is unclear.
To evaluate whether achieved and reduced lipid levels one year after acute coronary syndrome (ACS) are associated with subsequent major adverse cardiovascular events (MACE) in a real-world setting.
In 2,579 ACS survivors, achieving lipid targets one year after ACS was associated with lower relative risk of subsequent MACE over a median 5.5 years: LDL-C <1.8 mmol/L 29% lower relative risk (HR 0.71), LDL-C reduction ≥50% 37% lower relative risk (HR 0.63), non-HDL-C <2.2 mmol/L 35% lower relative risk (HR 0.65), and triglycerides <1.7 mmol/L 24% lower relative risk (HR 0.76). Absolute risk reduction was not reported. This is an observational cohort, so associations do not prove causation.
Methods Used
SPUM-ACS, a Swiss multicentric cohort of patients hospitalized with ACS between 2007 and 2021. 2,579 ACS survivors attended a one-year follow-up visit with lipid measurements and were followed for MACE (myocardial infarction, stroke, coronary revascularization, cardiovascular death) over a median of 5.5 years. Cox proportional hazards models were adjusted for age, sex, BMI, smoking status, statin therapy intensity, diabetes, systemic inflammatory disease, and creatinine.
Main Finding
One year after ACS, achieving LDL-C <1.8 mmol/L was associated with a 29% lower relative risk of MACE (HR 0.71, 95% CI 0.54-0.93); LDL-C reduction ≥50% with a 37% lower relative risk (HR 0.63, 95% CI 0.48-0.84); non-HDL-C <2.2 mmol/L with a 35% lower relative risk (HR 0.65, 95% CI 0.51-0.83); and triglycerides <1.7 mmol/L with a 24% lower relative risk (HR 0.76, 95% CI 0.62-0.94). Each 1 mmol/L reduction in LDL-C, non-HDL-C, and triglycerides was associated with 23%, 24%, and 14% lower relative risk, respectively. Absolute risk reduction was not reported in this study.
Confidence Level
Limited to moderate: large observational cohort with adjusted Cox models, but abstract-only review; no absolute risk reported; residual confounding possible; causal inference cannot be made.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Observational design cannot prove causation
- •Absolute risk reduction not reported in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
If you have had ACS, discuss with your clinician whether you are meeting guideline lipid targets: LDL-C below 1.8 mmol/L or a 50% or greater reduction from baseline, non-HDL-C below 2.2 mmol/L, and triglycerides below 1.7 mmol/L.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study watched people who had a heart attack or related problem and compared those with lower cholesterol to those with higher cholesterol over time. It can show a link between lower cholesterol and fewer future heart problems, but it cannot prove that the lower cholesterol itself caused the improvement. Only a randomized experiment could prove cause and effect.
Strengths
- Large sample size (2,579 ACS survivors)
- Multicentric Swiss cohort (SPUM-ACS)
- Long median follow-up of 5.5 years after the one-year post-ACS visit
Weaknesses
- Full methodology not available - based on abstract only
- Observational cohort design with no randomization
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study followed a large group of people for several years and tried to account for some differences like age and smoking, which is a strength. However, because people were not randomly assigned to different cholesterol levels, other hidden differences could explain the results. Also, we only have the summary, not the full details, so we cannot fully check how well it was done.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
38 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=2579)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with no randomization. Participants were not randomly assigned to different lipid levels or treatments, so residual confounding, selection bias, and reverse causation cannot be ruled out. Therefore, it can show associations but cannot prove that achieving lower lipid levels or targets causes the reduction in MACE.
COI Unknown
Could not determine conflict of interest status
The provided text is only an abstract and contains no conflict of interest or funding disclosure, so no COI assessment can be made.
Abstract only; no author affiliations, COI, or funding sections included. The cohort name SPUM-ACS may have external funding, but this is not stated in the provided text.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
10 researchersIf this is your work, this is how we attribute it on Fit Body Science. Cédric Follonier is listed as the lead author.
- Centre universitaire de médecine générale et santé publique, Lausanne
Cited in 1 claim